Thymoma and thymic carcinomas

Marta Scorsetti, Francesco Leo, Annalisa Trama, Rolando D'Angelillo, D. Serpico, Marianna Macerelli, Paolo Andrea Zucali, Gemma Gatta, Marina Chiara Garassino

Research output: Contribution to journalArticle

Abstract

Thymomas Ts and thymic carcinomas TCs are rare tumours of the mediastinum with an incidence rate of 1.7/million per year in Europe.Histological classification is based on rate of non-malignant-appearing thymic epithelial cells and proportions of lymphocytes A, AB, B1, B2, B3, and C, while staging system concerns localisation of the involved areas.Surgery is the mainstay of treatment with a 10-year survival of 80%, 78%, 75%, and 42% for stages I, II, III and IV, respectively, with an R0 resection.Radiotherapy has a role in selected cases stage III patients or R1-2 residual and platinum-based chemotherapy remains the standard of care for patients with advanced disease.A multimodality approach would be advisable when surgery is not recommended. Since molecular aberrations are poorly understood and few responses are reported, targeted therapies are yet being studied.In this review, we describe key aspects of clinical management for Ts and TCs.

Original languageEnglish
Pages (from-to)332-350
Number of pages19
JournalCritical Reviews in Oncology/Hematology
Volume99
DOIs
Publication statusPublished - Mar 1 2016

Fingerprint

Thymoma
Mediastinum
Standard of Care
Platinum
Radiotherapy
Epithelial Cells
Lymphocytes
Drug Therapy
Survival
Incidence
Therapeutics
Neoplasms

Keywords

  • Chemotherapy
  • Diagnosis
  • Radiotherapy
  • Surgery
  • Targeted therapies
  • Thymic carcinoma
  • Thymomas

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Thymoma and thymic carcinomas. / Scorsetti, Marta; Leo, Francesco; Trama, Annalisa; D'Angelillo, Rolando; Serpico, D.; Macerelli, Marianna; Zucali, Paolo Andrea; Gatta, Gemma; Garassino, Marina Chiara.

In: Critical Reviews in Oncology/Hematology, Vol. 99, 01.03.2016, p. 332-350.

Research output: Contribution to journalArticle

Scorsetti, Marta ; Leo, Francesco ; Trama, Annalisa ; D'Angelillo, Rolando ; Serpico, D. ; Macerelli, Marianna ; Zucali, Paolo Andrea ; Gatta, Gemma ; Garassino, Marina Chiara. / Thymoma and thymic carcinomas. In: Critical Reviews in Oncology/Hematology. 2016 ; Vol. 99. pp. 332-350.
@article{f8ae9df578de46288a15a7434c056ef1,
title = "Thymoma and thymic carcinomas",
abstract = "Thymomas Ts and thymic carcinomas TCs are rare tumours of the mediastinum with an incidence rate of 1.7/million per year in Europe.Histological classification is based on rate of non-malignant-appearing thymic epithelial cells and proportions of lymphocytes A, AB, B1, B2, B3, and C, while staging system concerns localisation of the involved areas.Surgery is the mainstay of treatment with a 10-year survival of 80{\%}, 78{\%}, 75{\%}, and 42{\%} for stages I, II, III and IV, respectively, with an R0 resection.Radiotherapy has a role in selected cases stage III patients or R1-2 residual and platinum-based chemotherapy remains the standard of care for patients with advanced disease.A multimodality approach would be advisable when surgery is not recommended. Since molecular aberrations are poorly understood and few responses are reported, targeted therapies are yet being studied.In this review, we describe key aspects of clinical management for Ts and TCs.",
keywords = "Chemotherapy, Diagnosis, Radiotherapy, Surgery, Targeted therapies, Thymic carcinoma, Thymomas",
author = "Marta Scorsetti and Francesco Leo and Annalisa Trama and Rolando D'Angelillo and D. Serpico and Marianna Macerelli and Zucali, {Paolo Andrea} and Gemma Gatta and Garassino, {Marina Chiara}",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.critrevonc.2016.01.012",
language = "English",
volume = "99",
pages = "332--350",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - Thymoma and thymic carcinomas

AU - Scorsetti, Marta

AU - Leo, Francesco

AU - Trama, Annalisa

AU - D'Angelillo, Rolando

AU - Serpico, D.

AU - Macerelli, Marianna

AU - Zucali, Paolo Andrea

AU - Gatta, Gemma

AU - Garassino, Marina Chiara

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Thymomas Ts and thymic carcinomas TCs are rare tumours of the mediastinum with an incidence rate of 1.7/million per year in Europe.Histological classification is based on rate of non-malignant-appearing thymic epithelial cells and proportions of lymphocytes A, AB, B1, B2, B3, and C, while staging system concerns localisation of the involved areas.Surgery is the mainstay of treatment with a 10-year survival of 80%, 78%, 75%, and 42% for stages I, II, III and IV, respectively, with an R0 resection.Radiotherapy has a role in selected cases stage III patients or R1-2 residual and platinum-based chemotherapy remains the standard of care for patients with advanced disease.A multimodality approach would be advisable when surgery is not recommended. Since molecular aberrations are poorly understood and few responses are reported, targeted therapies are yet being studied.In this review, we describe key aspects of clinical management for Ts and TCs.

AB - Thymomas Ts and thymic carcinomas TCs are rare tumours of the mediastinum with an incidence rate of 1.7/million per year in Europe.Histological classification is based on rate of non-malignant-appearing thymic epithelial cells and proportions of lymphocytes A, AB, B1, B2, B3, and C, while staging system concerns localisation of the involved areas.Surgery is the mainstay of treatment with a 10-year survival of 80%, 78%, 75%, and 42% for stages I, II, III and IV, respectively, with an R0 resection.Radiotherapy has a role in selected cases stage III patients or R1-2 residual and platinum-based chemotherapy remains the standard of care for patients with advanced disease.A multimodality approach would be advisable when surgery is not recommended. Since molecular aberrations are poorly understood and few responses are reported, targeted therapies are yet being studied.In this review, we describe key aspects of clinical management for Ts and TCs.

KW - Chemotherapy

KW - Diagnosis

KW - Radiotherapy

KW - Surgery

KW - Targeted therapies

KW - Thymic carcinoma

KW - Thymomas

UR - http://www.scopus.com/inward/record.url?scp=84959457888&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84959457888&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2016.01.012

DO - 10.1016/j.critrevonc.2016.01.012

M3 - Article

VL - 99

SP - 332

EP - 350

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

ER -